DBV Technologies S.A. (DBVTF)
OTCMKTS · Delayed Price · Currency is USD
4.800
+0.900 (23.08%)
At close: Jan 27, 2026
DBV Technologies Revenue
Revenue (ttm)
5.50M
Revenue Growth
-56.04%
P/S Ratio
237.19
Revenue / Employee
47.03K
Employees
117
Market Cap
1.31B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | 16.71M | 2.42M | 16.90% |
| Dec 31, 2017 | 14.29M | 4.73M | 49.50% |
| Dec 31, 2016 | 9.56M | 2.86M | 42.76% |
| Dec 31, 2015 | 6.70M | 933.42K | 16.20% |
| Dec 31, 2014 | 5.76M | 500.37K | 9.51% |
| Dec 31, 2013 | 5.26M | 1.60M | 43.65% |
| Dec 31, 2012 | 3.66M | 1.24M | 51.01% |
| Dec 31, 2011 | 2.43M | 143.69K | 6.30% |
| Dec 31, 2010 | 2.28M | 734.19K | 47.44% |
| Dec 31, 2009 | 1.55M | 93.10K | 6.40% |
| Dec 31, 2008 | 1.45M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioStem Technologies | 292.21M |
| Vaxart | 148.20M |
| Silence Therapeutics | 25.83M |
| Nuo Therapeutics | 2.61M |
| Northwest Biotherapeutics | 937.00K |
| Arch Biopartners | 198.11K |